These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32535481)

  • 21. Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis.
    Inker LA; Heerspink HJL; Tighiouart H; Chaudhari J; Miao S; Diva U; Mercer A; Appel GB; Donadio JV; Floege J; Li PKT; Maes BD; Locatelli F; Praga M; Schena FP; Levey AS; Greene T
    Am J Kidney Dis; 2021 Sep; 78(3):340-349.e1. PubMed ID: 33775708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria.
    Lv J; Liu L; Hao C; Li G; Fu P; Xing G; Zheng H; Chen N; Wang C; Luo P; Xie D; Zuo L; Li R; Mao Y; Dong S; Zhang P; Zheng H; Wang Y; Qin W; Wang W; Li L; Jiao W; Fang J; Zhang H
    Kidney Int Rep; 2023 Mar; 8(3):499-506. PubMed ID: 36938094
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High serum IgA/C3 ratio better predicts a diagnosis of IgA nephropathy among primary glomerular nephropathy patients with proteinuria ≤ 1 g/d: an observational cross-sectional study.
    Gong WY; Liu M; Luo D; Liu FN; Yin LH; Li YQ; Zhang J; Peng H
    BMC Nephrol; 2019 Apr; 20(1):150. PubMed ID: 31039758
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the effects of valsartan plus activated vitamin D versus valsartan alone in IgA nephropathy with moderate proteinuria.
    Xiaowei L; Bo W; Li L; Peng Z
    Int Urol Nephrol; 2020 Jan; 52(1):129-136. PubMed ID: 31768803
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of corticosteroid therapy for IgA nephropathy patients stratified by kidney function and proteinuria.
    Nagasawa Y; Yamamoto R; Shinzawa M; Shoji T; Hasuike Y; Nagatoya K; Yamauchi A; Hayashi T; Kuragano T; Moriyama T; Isaka Y
    Clin Exp Nephrol; 2020 Oct; 24(10):927-934. PubMed ID: 32642919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy.
    Lafayette R; Barbour S; Israni R; Wei X; Eren N; Floege J; Jha V; Kim SG; Maes B; Phoon RKS; Singh H; Tesař V; Lin CJF; Barratt J
    Kidney Int; 2024 Jun; 105(6):1306-1315. PubMed ID: 38552841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled Trial.
    Hou JH; Le WB; Chen N; Wang WM; Liu ZS; Liu D; Chen JH; Tian J; Fu P; Hu ZX; Zeng CH; Liang SS; Zhou ML; Zhang HT; Liu ZH
    Am J Kidney Dis; 2017 Jun; 69(6):788-795. PubMed ID: 28215945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term outcome of IgA nephropathy with minimal change disease: a comparison between patients with and without minimal change disease.
    Li XW; Liang SS; Le WB; Cheng SQ; Zeng CH; Wang JQ; Liu ZH
    J Nephrol; 2016 Aug; 29(4):567-73. PubMed ID: 26537358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics.
    Wong MG; Lv J; Hladunewich MA; Jha V; Hooi LS; Monaghan H; Zhao M; Barbour S; Reich HN; Cattran D; Glassock R; Levin A; Jardine MJ; Wheeler DC; Woodward M; Billot L; Chan TM; Liu ZH; Johnson DW; Cass A; Feehally J; Floege J; Remuzzi G; Wu Y; Agarwal R; Zhang H; Perkovic V;
    Am J Nephrol; 2021; 52(10-11):827-836. PubMed ID: 34731857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The difference between patients with nephrotic syndrome and nephrotic-range proteinuria in IgA nephropathy: a propensity score matched cohort study.
    Li H; Wang F; Jia J; Yan T; Liu Y; Lin S
    BMC Nephrol; 2022 Apr; 23(1):163. PubMed ID: 35488221
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunosuppressive agents for treating IgA nephropathy.
    Vecchio M; Bonerba B; Palmer SC; Craig JC; Ruospo M; Samuels JA; Molony DA; Schena FP; Strippoli GF
    Cochrane Database Syst Rev; 2015 Aug; (8):CD003965. PubMed ID: 26235292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effectiveness and safety of corticosteroid therapy for IgA nephropathy with crescents: a prospective, randomized, controlled study.
    Liang M; Xiong L; Li A; Zhou J; Huang Y; Huang M; Zhang X; Shi H; Su N; Wei Y; Jiang Z
    BMC Nephrol; 2022 Jan; 23(1):40. PubMed ID: 35062886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Positive renal familial history in IgA nephropathy is associated with worse renal outcomes: a single-center longitudinal study.
    Sato Y; Tsukaguchi H; Higasa K; Kawata N; Inui K; Linh TNT; Quynh TTH; Yoshihiko I; Koiwa F; Yoshimura A
    BMC Nephrol; 2021 Jun; 22(1):230. PubMed ID: 34147067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicopathological Features to Predict Progression of IgA Nephropathy with Mild Proteinuria.
    Chen D; Liu J; Duan S; Chen P; Tang L; Zhang L; Feng Z; Cai G; Wu J; Chen X
    Kidney Blood Press Res; 2018; 43(2):318-328. PubMed ID: 29529608
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High Neutrophil-To-Lymphocyte Ratio Is an Independent Risk Factor for End Stage Renal Diseases in IgA Nephropathy.
    Wang S; Dong L; Pei G; Jiang Z; Qin A; Tan J; Tang Y; Qin W
    Front Immunol; 2021; 12():700224. PubMed ID: 34456912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of clinical, pathological and long-term renal outcomes of children with Henoch-Schonlein purpura nephritis and IgA nephropathy.
    Torun Bayram M; Heybeli C; Yıldız G; Soylu A; Celik A; Sarioglu S; Kavukçu S
    Int Urol Nephrol; 2022 Aug; 54(8):1925-1932. PubMed ID: 34846620
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.
    Rauen T; Eitner F; Fitzner C; Sommerer C; Zeier M; Otte B; Panzer U; Peters H; Benck U; Mertens PR; Kuhlmann U; Witzke O; Gross O; Vielhauer V; Mann JF; Hilgers RD; Floege J;
    N Engl J Med; 2015 Dec; 373(23):2225-36. PubMed ID: 26630142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
    Heerspink HJL; Radhakrishnan J; Alpers CE; Barratt J; Bieler S; Diva U; Inrig J; Komers R; Mercer A; Noronha IL; Rheault MN; Rote W; Rovin B; Trachtman H; Trimarchi H; Wong MG; Perkovic V;
    Lancet; 2023 May; 401(10388):1584-1594. PubMed ID: 37015244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined Immunosuppressive Treatment May Improve Short-Term Renal Outcomes in Chinese Patients with Advanced IgA Nephropathy.
    Tan L; Tang Y; Peng W; Mathew BS; Qin W
    Kidney Blood Press Res; 2018; 43(4):1333-1343. PubMed ID: 30099439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.